

**Adlyxin (lixisenatide) Prior Authorization Request Form** Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: \_\_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: https://magellanrx.com/member/external/commercial/common/doc/en-us/phi\_disclosure\_authorization.pdf

## PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_\_ AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
<b>REQUESTOR</b> (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
<b>NEW THERAPY</b> DURATION OF THERAPY (SPE	<b>RENEWAL</b> CIFIC DATES):	IF RENEWAL: DATE THERAPY INITIATED:			

Continued on next page.

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 10.1.2022 CAT0010







## Adlyxin (lixisenatide) Prior Authorization Request Form Caterpillar Prescription Drug Benefit



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
□ Type II diabetes □ Other diagnosis:				
	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
PRIOR AUTHORIZATION.         Lab Values:         Was the patient's most recent HbA1c in the past 6 months or prior to starting the requested medication 7.0% or greater? □ Yes □ No         Documentation of HbA1c level required.         Is the patient's estimated glomerular filtration rate (GFR) less than or equal to 45 mL/min/1.73 m2? □ Yes □ No         Does the patient currently have a serum creatinine level exceeding 1.8 mg/dL or an estimated GFR less than 30 mL/min/1.73 m2? □ Yes □ No         Does the patient currently have a serum creatinine level exceeding 1.8 mg/dL or an estimated GFR less than 30 mL/min/1.73 m2? □ Yes □ No         Documentation required.         Clinical information:         Has the patient tried or is the patient currently taking metformin? □ Yes □ No         Has treatment with metformin been avoided due to lactic acidosis or elevated liver enzymes? □ Yes □ No         Does the patient have advanced liver disease with at least one of the following? □ Yes □ No         If yes, please select:         □ Ascites         □ Cirrhosis				
<ul> <li>Hepatic encephalopathy</li> <li>Portal hypertension</li> <li>Is the patient currently taking any of the select:</li> <li>Janumet/Janumet XR (sitagliptin/metion)</li> <li>Jentadueto/Jentadueto XR (linagliptin)</li> <li>Kazano (alogliptin/metformin) </li> <li>Kosina (alogliptin)</li> <li>Onglyza (saxagliptin)</li> </ul>	etformin) in/metformin)			

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 10.1.2022 CAT0010



Mage





MEMBER'S LAST NAME:

## MEMBER'S FIRST NAME:

Oseni (alogliptin/pioglitazone)

Tradjenta (linagliptin)

Glyxambi (empagliflozin/linagliptin)

□ Seglujan (ertugliflozin/sitagliptin)

Qtern (dapagloflozin/saxagliptin)

If the patient is taking any of the above medications, will concomitant therapy with those medications be discontinued?  $\Box$  Yes  $\Box$  No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: \_

Date: \_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

## FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



